Usually, when one insider buys stock, it might not be a monumental event. But when multiple insiders are buying ...

Shares of NASDAQ ZVRA opened at $8.11 on Wednesday. Zevra Therapeutics has a 1 year low of $4.20 and a 1 year high of $9.76. The company has a market capitalization of $432.88 million, a price-to ...

Zevra Therapeutics (NASDAQ:ZVRA – Get Free Report) last released its quarterly earnings results on Tuesday, November 12th.The company reported ($0.69) earnings per share for the quarter, missing ...

Cantor Fitzgerald assumed coverage of Zevra Therapeutics (ZVRA) with an Overweight rating and $25 price target Zevra is a rare disease, ...

Zevra Therapeutics (ZVRA – Research Report) received a Buy rating and a price target from Cantor Fitzgerald analyst Kristen Kluska today. The company’s shares closed yesterday at $8.24.

With the business potentially at an important milestone, we thought we'd take a closer look at Zevra Therapeutics, Inc.'s (NASDAQ:ZVRA) future prospects. Zevra Therapeutics, Inc. discovers and ...

Cantor Fitzgerald assumed coverage of Zevra Therapeutics (ZVRA) with an Overweight rating and $25 price target Zevra is a rare disease, commercial-stage biotechnology company with two approved ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...